NPS Pharmaceuticals news from FierceBiotech
NewsGSK ends NPS's osteoporosis drug study
Bad news for NPS Pharmaceuticals: the company announced late Thursday that its partner GlaxoSmithKline would abandon a Phase II study of Ronacalaret, an osteoporosis drug. According to SEC filings... Read more...
C&L: Milano tapped to run ViroPharma
ViroPharma has named Vincent Milano to succeed Michel de Rosen as president and chief executive. De Rosen will continue as non-executive chairman. Also, Daniel Soland has been named COO. NPS... Read more...
ALSO NOTED: Acorda shares bounce on new data; Endo CEO hits the exit door; BioSante in protocol deal; and much more...
> Shares of Acorda Therapeutics took a big bounce yesterday when the company announced new data demonstrating that its multiple sclerosis drug Fampridine-SR does not raise heart-related risks... Read more...
ALSO NOTED: More takeover targets for Big Pharma; Byetta trial delivers positive data; and much more...
> Industry watchers can't resist identifying takeover targets for Big Pharma. This week, the Motley Fool's radar is picking up Sepracor--which announced layoffs yesterday after a few tough... Read more...
NPS pockets $30M, parts ways with AstraZeneca
NPS Pharmaceuticals and AstraZeneca are ending their six-year-old collaboration to develop new drugs for metabotropic glutamate receptors, or mGluRs. AstraZeneca is paying NPS $30 million for the... Read more...
| Press ReleasesPRESS RELEASE: NPS Pharmaceuticals Says CFO to Leave, Replacement Named NPS Pharmaceuticals Says CFO to Leave, Replacement Named BEDMINSTER, N.J., Nov. 13 -- NPS Pharmaceuticals announced today the promotion of Andrew Rackear to senior vice president, legal affairs, and Read more >> PRESS RELEASE: Nycomed Confirms Commitment to GATTEX Partnership; NPS to Receive $25 Million Payment Nycomed Confirms Commitment to GATTEX Partnership; NPS to Receive $25 Million Payment BEDMINSTER, N.J., Oct. 31 -- NPS Pharmaceuticals, Inc. announced today that Nycomed, after an in-depth review of Read more >> PRESS RELEASE: NPS Pharmaceuticals PREOS Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism NPS Pharmaceuticals PREOS Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism PARSIPPANY, N.J., Sept. 19 -- NPS Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Read more >> |
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
